Common Antibiotic Found To Carry Heart Risk
Main Category: Infectious Diseases / Bacteria / VirusesAlso Included In: Cardiovascular / CardiologyArticle Date: 17 May 2012 – 4:00 PDT
Current ratings for:’Common Antibiotic Found To Carry Heart Risk’
Vanderbilt researchers have discovered a rare, but important risk posed by the antibiotic azithromycin, commonly called a “Z-pack.” The study found a 2.5-fold higher risk of cardiovascular death in the first five days of taking azithromycin when compared with another common antibiotic or no antibiotics at all.
Wayne A. Ray, Ph.D., professor of Preventive Medicine, and C. Michael Stein, M.B.Ch.B., the Dan May Chair in Medicine and professor of Pharmacology, collaborated on the research published in the May 17 edition of the New England Journal of Medicine.
Azithromycin, commonly called a “Z-pack” is one of the most popular treatments for bacterial sinus infections and bronchitis. Although it was previously considered to carry tiny to no cardiac risk, the researchers noted well-documented reports in the published literature as FDA database reports linking azithromycin with serious arrhythmias. Based on this evidence, the Vanderbilt researchers sought to analyze cardiovascular deaths in patients who were taking the antibiotic.
Tennessee Medicaid (TennCare) patient records were analyzed from 1992 to 2006.
The researchers took many steps in this large, observational, population-based study to rule out other reasons for the increase in cardiovascular deaths in patients taking azithromycin. About 348,000 recorded prescriptions of azithromycin were compared with millions of similar records from people who were not treated with antibiotics or were treated with other antibiotics. The primary comparison was with amoxicillin, an antibiotic that is considered to be heart safe and is used in similar clinical circumstances as azithromycin.
While the absolute number of deaths was quite low, relative to amoxicillin, there were about 47 more deaths per million courses of therapy in those taking the azithromycin. That risk increased to 245 additional cardiovascular deaths per million in patients already known to have a high risk for heart problems.
The researchers emphasized that the decision to prescribe any antibiotic requires careful balancing of both potential benefits and risks. This calculation must think about the severity of the infection, the susceptibility of the organism, the availability of alternative antibiotics and adverse effects.
“We believe this study adds important information on the risk profile for azithromycin,” stated Ray. “For patients with elevated cardiovascular risk and infections for which there are alternative antibiotics, the cardiovascular effects of azithromycin may be an important clinical consideration.”
Please note: If no author information is provided, the source is cited instead.
‘Common Antibiotic Found To Carry Heart Risk’
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Related News:
- Novel therapeutic advancement in search for heart muscle progenitor cells: New hope for heart attack patients
- Flu Vaccines May Protect the Heart Too
- Weight Loss Does Not Lower Heart Disease Risk from Type 2 Diabetes
- Haryana Plans To Set Up More Cardiac Care Units
- Cardiac Dimensions commences commercialization of CARILLON mitral contour system in Europe
- Move Over Olive Oil!
- Move Over Olive Oil!
- Heart Healthy Supplement?
- NIH Pilot Study Shows Feasability of MRI to Guide Heart Catheter Procedures
- Increased risk of heart failure and cardiovascular death linked to thickening of heart’s right ventricle
Details :
Submited at Thursday, May 17th, 2012 at 4:00 pm on Uncategorized by sofia
Comment RSS 2.0 - leave a comment - trackback


